Meek's bold step down from Ipsen upsets investors

18 December 2019
david_meek_large-1-

In a surprise move, Ipsen (Euronext: IPN) chief executive David Meek (pictured above) has quit his position at the French drugmaker to take the helm at a small gene therapy startup, FerGene.

A subsidiary of Swiss firm Ferring Pharmaceutical, FerGene was founded in November 2019 with a $400 million investment from Blackstone Life Sciences. Ferring put in another $170 million.

The new company is developing nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for certain people with bladder cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology